Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002246 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00002246 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 20 participants.
The verdict
NCT00002246, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to see if adding stavudine (d4T) to anti-HIV drug regimens (with or without zidovudine, ZDV) can improve symptoms of AIDS Dementia Complex (ADC, problems involving the brain or spinal cord) in HIV-positive patients.
Interventions
- DRUG Stavudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1997-10 |
| Est. Completion | 1999-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002246
The ClinicalTrials.gov registry entry for NCT00002246 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stavudine is the first listed.
NCT00002246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002246 about?
NCT00002246 is a clinical study titled "A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex". The purpose of this study is to see if adding stavudine (d4T) to anti-HIV drug regimens (with or without zidovudine, ZDV) can improve symptoms of AIDS Dementia Complex (ADC, problems involving the brain or spinal cord) in HIV-positive patients.
What is the current status of trial NCT00002246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 1997-10. Estimated completion is 1999-03.
What interventions are being tested in trial NCT00002246?
The interventions under investigation include: Stavudine (DRUG).
Who is sponsoring clinical trial NCT00002246?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.